We wish to Inform that Asarfi Hospital Limited has signed a Memorandum of Undersatanding ( MoU) with Gleneagles Hospital, Chennai, to set up Jharkhand''s first Multi Organ Transplant Unit ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.9 pts more than Nifty Microcap 250 and 2.6 pts more than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Asarfi Hospital has signed a Memorandum of Understanding (MoU) with Gleneagles Hospital, Chennai, to set up Jharkhand's first Multi-Organ Transplant Unit at its Dhanbad facility. The new centre will offer transplant services for heart, lungs, kidneys, liver, and bone marrow — services previously unavailable in the state, forcing patients to travel to Delhi, Mumbai, Kolkata, or Chennai. A dedicated floor has been allocated; diagnostic and consultation services will begin shortly, while full transplant procedures will start only after state health authority approvals. The hospital is already empanelled under the Jharkhand Government's MGBUY scheme, which provides eligible patients ₹15 to ₹25 lakhs in financial assistance. Gleneagles, known for India's first adult liver swap and single lung transplant, will provide specialist expertise.
Positive development for shareholders — this expands Asarfi's service line into high-value tertiary and quaternary care, opens a new revenue stream, and elevates the hospital's brand through association with a marquee healthcare chain. It also positions the company as the leading advanced-care provider in Eastern India, which could support future growth and valuation.